PriceTargets.com logo

Acasti Pharma - ACST Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 110.53%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.85 As of 04/22/2024 01:00 AM ET
▼ -0.02 (-0.70%)

This chart shows the closing price for ACST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acasti Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACST

Analyst Price Target is $6.00
▲ +110.53% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Acasti Pharma in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 110.53% upside from the last price of $2.85.

This chart shows the closing price for ACST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Acasti Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2024Craig HallumInitiated CoverageBuy$6.00Low
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$15.00Low
12/19/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$15.00Low
12/15/2022HC WainwrightInitiated CoverageBuy$14.40Low
12/21/2021OppenheimerInitiated CoverageOutperform$36.00High
9/2/2020AegisDowngradeBuy ➝ HoldHigh
9/1/2020B. RileyLower TargetBuy ➝ Neutral$96.00 ➝ $24.00High
8/31/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
8/14/2020HC WainwrightReiterated RatingBuy$144.00High
7/6/2020B. RileyUpgradeNeutral ➝ Buy$96.00High
6/30/2020Echelon Wealth PartnersReiterated RatingBuy$67.20Low
6/30/2020OppenheimerReiterated RatingBuy$336.00High
6/23/2020B. RileyDowngradeHold$96.00High
5/6/2020AegisLower TargetBuy$144.00 ➝ $103.20High
2/18/2020HC WainwrightLower TargetBuy$288.00 ➝ $144.00Medium
1/22/2020OppenheimerReiterated RatingBuy$336.00Low
1/13/2020B. RileyDowngradeBuy ➝ Neutral$96.00High
1/8/2020Echelon Wealth PartnersReiterated RatingBuy$192.00Medium
12/26/2019OppenheimerReiterated RatingBuy$336.00Low
12/24/2019B. RileyReiterated RatingBuy$384.00High
8/29/2019B. RileyInitiated CoverageBuy$372.00High
8/15/2019HC WainwrightReiterated RatingBuyHigh
7/18/2019CIBCInitiated CoverageOutperform ➝ Outperform$336.00High
7/18/2019OppenheimerInitiated CoverageOutperform$336.00 ➝ $336.00High
7/9/2019AegisInitiated CoverageBuyMedium
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$288.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Acasti Pharma logo
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: $2.85
Low: $2.81
High: $2.91

50 Day Range

MA: $3.32
Low: $2.45
High: $3.48

52 Week Range

Now: $2.85
Low: $1.72
High: $3.84

Volume

9,839 shs

Average Volume

29,214 shs

Market Capitalization

$26.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Acasti Pharma?

The following Wall Street analysts have issued research reports on Acasti Pharma in the last twelve months: Craig Hallum.
View the latest analyst ratings for ACST.

What is the current price target for Acasti Pharma?

1 Wall Street analysts have set twelve-month price targets for Acasti Pharma in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 110.5%. Craig Hallum has the highest price target set, predicting ACST will reach $6.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $6.00 for Acasti Pharma in the next year.
View the latest price targets for ACST.

What is the current consensus analyst rating for Acasti Pharma?

Acasti Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACST will outperform the market and that investors should add to their positions of Acasti Pharma.
View the latest ratings for ACST.

What other companies compete with Acasti Pharma?

Other companies that are similar to Acasti Pharma include LianBio, Freeline Therapeutics, Brainstorm Cell Therapeutics, Lipocine and Alaunos Therapeutics. Learn More about companies similar to Acasti Pharma.

How do I contact Acasti Pharma's investor relations team?

Acasti Pharma's physical mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company's listed phone number is 45-0686-4555 and its investor relations email address is [email protected]. The official website for Acasti Pharma is www.acastipharma.com. Learn More about contacing Acasti Pharma investor relations.